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Abstract
Background: Differentiation of Parkinson’s disease (PD) from the various types of atypical parkinsonism (AP) such as
multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), corticobasal
syndrome (CBS) and vascular parkinsonism (VP), can be challenging, especially early in the disease course when
symptoms overlap. A major unmet need in the diagnostic workup of these disorders is a diagnostic tool that
differentiates the various disorders, preferably in the earliest disease stages when the clinical presentation is similar.
Many diagnostic tests have been evaluated, but their added value was studied mostly in retrospective case-control
studies that included patients with a straightforward clinical diagnosis. Here, we describe the design of a
prospective cohort study in patients with parkinsonism in an early disease stage who have an uncertain clinical
diagnosis. Our aim is to evaluate the diagnostic accuracy of (1) detailed clinical examination by a movement
disorder specialist, (2) magnetic resonance imaging (MRI) techniques and (3) cerebrospinal fluid (CSF) biomarkers.
Methods/design: Patients with parkinsonism with an uncertain clinical diagnosis and a disease course less than
three years will be recruited. Patients will undergo extensive neurological examination, brain MRI including
conventional and advanced sequences, and a lumbar puncture. The diagnosis (including level of certainty) will be
defined by a movement disorders expert, neuroradiologist and neurochemist based on clinical data, MRI results and
CSF results, respectively. The clinical diagnosis after three years’ follow-up will serve as the “gold standard” reference
diagnosis, based on consensus criteria and as established by two movement disorder specialists (blinded to the test
results). Diagnostic accuracy of individual instruments and added value of brain MRI and CSF analysis after
evaluation by a movement disorder expert will be calculated, expressed as the change in percentage of individuals
that are correctly diagnosed with PD or AP.
Discussion: This study will yield new insights into the diagnostic value of clinical evaluation by a movement
disorder specialist, brain MRI and CSF analysis in discriminating PD from AP in early disease stages. The outcome
has the potential to help clinicians in choosing the optimal diagnostic strategy for patients with an uncertain
clinical diagnosis.
Trial registration: NCT01249768, registered November 26 2010.
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Background
Differentiation between Parkinson’s Disease (PD) and
the various forms of atypical parkinsonism (AP) can be
difficult, especially early in the disease course. This is
due to overlap in clinical symptoms, certainly when the
clinical picture has not yet developed fully. Forms of AP
such as multiple system atrophy (MSA), progressive
supranuclear palsy (PSP) or corticobasal syndrome
(CBS) follow a more malignant disease course than PD
and, unlike PD, generally do not respond well to dopa-
minergic therapy.
While difficult, a correct diagnosis is important for
adequate disease management and patient counseling, as
well as for research purposes. If, in the future, any
disease-modifying therapy becomes available, then reli-
able diagnostic tools will be essential to distinguish PD
from AP at the earliest possible stage.
Because there is not yet a reliable objective test for PD
and AP, expert opinion remains the gold standard for
the clinical diagnosis. In the hands of a movement
disorders specialist, the diagnostic accuracy is higher
(90%) compared to judgment by a general neurologist
(76%) [1, 2]. Although the clinical diagnosis after several
years of follow-up correlates highly with the neuropatho-
logical diagnosis upon post-mortem examination, the
diagnostic accuracy of the initial diagnosis varies greatly,
and can be as low as 30% [1, 3–5]. When a clinician has
little doubt about the diagnosis, ancillary investigations
have hardly any diagnostic value. But when the clinical
picture is puzzling, which is often the case early in the
disease course, reliable biomarkers are needed for accur-
ate and early differentiation between PD and AP.
Brain MRI is nowadays part of the diagnostic workup
of patients with suspected parkinsonism, mainly to
exclude secondary causes of parkinsonism (e.g. tumor,
hydrocephalus, multiple sclerosis, vascular parkinson-
ism). Conventional MRI can demonstrate abnormalities
characteristic for various AP syndromes, such as
putaminal or olivopontocerebellar atrophy in MSA, mid-
brain atrophy in PSP and asymmetric regional cortical
atrophy in CBS.
Due to limited sensitivity of these MRI abnormalities
(e.g. 68% for cerebellar atrophy and 59% for putaminal
atrophy), their contribution to the clinically based diag-
nosis is limited [6]. These abnormalities often occur late
in the disease course, which make them of less diagnos-
tic value in early disease stages. However, advances in
neuroimaging techniques are promising to provide new
biomarkers for improved differentiation between the
different parkinsonian syndromes.
Magnetic resonance volumetry (MRV), diffusion ten-
sor imaging (DTI), susceptibility weighted imaging
(SWI) and resting state functional magnetic resonance
imaging (rs-fMRI) are examples of new MR techniques
which have become available [7–10]. However, these
new techniques are often difficult to interpret for the in-
dividual patient, since MRI patterns are investigated on
a group level. Moreover, validated diagnostic criteria are
generally lacking. For example, DTI studies found alter-
ations in fractional anisotropy and mean diffusivity in
the substantia nigra in PD patients and in the cerebel-
lum, pons, cerebellar peduncles and putamen in MSA
patients. Furthermore, increased iron accumulation in
the substantia nigra on SWI sequences is suggestive
for PD as is increased putaminal hypointensity for
MSA [7, 11, 12]. Rs-fMRI has been applied to assess
functional abnormalities in neural networks of PD pa-
tients. Several studies identified PD-specific network
patterns compared to healthy controls, but if these
patterns differ from AP cases is yet unknown [13].
Furthermore, research on cerebrospinal fluid (CSF)
biomarkers has strongly developed over the past decade.
Analysis of brain specific proteins in CSF can be of value
in distinguishing PD from AP. In PD patients, concen-
trations of brain specific proteins and neurotransmitter
metabolites are generally within normal ranges, whereas
in AP aberrant levels of these proteins and metabolites
can be found. Currently, neurofilament light chain
(NFL), total and phosphorylated tau (t-tau and p-tau), α-
synuclein (α-syn) and amyloid-β42 (Aβ42) seem to be
the most promising biomarkers for the differential diag-
nosis of parkinsonian syndromes. NFL levels are
increased in AP compared with PD and healthy controls,
tau proteins are elevated in CBS, while Aβ42 and tau
are associated with cognitive decline (dementia) in PD
and DLB [14–21].
Given the complexity of parkinsonian syndromes it is
likely that neither a single clinical test nor a single bio-
marker can differentiate between the different parkinson-
ian syndromes. A combination of parameters could
however improve diagnostic accuracy [14, 15, 18, 19, 21].
On the other hand, MRI is time-consuming and expen-
sive, CSF analysis requires a lumbar puncture and many
centers lack a neurologist with experience in movement
disorders. More knowledge about the diagnostic value
of each test could help clinicians in selecting the best
available test.
With this prospective cohort study, we aim to gain
insight in which single or combined ancillary investiga-
tion (including the opinion of a movement disorder
specialist) will have the highest diagnostic yield for dis-
crimination of PD and AP in early disease stage when
diagnostic uncertainty is high.
Methods/design
Study design
A prospective observational cohort study to assess the
diagnostic value of clinical evaluation by a movement
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disorder specialist, brain MRI and CSF analysis in dis-
criminating different forms of parkinsonism early in the
disease course. The Medical Ethics Committee Arnhem-
Nijmegen approved the study. Written informed consent
will be obtained from all patients after detailed explan-
ation of the procedures.
Objectives
The main objective of our study is to determine the
diagnostic accuracy of detailed clinical examination by a
movement disorder specialist, conventional and
advanced brain MRI techniques and CSF analysis to dif-
ferentiate PD from AP in clinically uncertain cases. Sec-
ondary objective is to identify potential variables for
differentiation between PD and AP.
Third objective is to identify potential discriminative
variables between the various forms of AP.
Study population
Patients will be recruited from our outpatient movement
disorder clinic and outpatient neurology clinics of refer-
ring general hospitals. Inclusion criteria are clinical signs
and symptoms of parkinsonism (hypokinetic-rigid
syndrome) with uncertain clinical diagnosis and disease
duration less than three years. Exclusion criteria are age
below 18 years and unstable co-morbidity. Inclusion and
exclusion criteria are provided in Table 1.
Clinical examination
Evaluation by a movement disorder specialist
All patients will be interviewed and examined by a
movement disorder specialist at the outpatient neur-
ology department of the Radboud university medical
center in Nijmegen (The Netherlands).
Structured interview
Standardized questionnaires on demographics, medical
history, cardiovascular risk factors, activities in daily
living, medication use, disease onset, clinical signs, most
affected body site, balance and fear of falling will be
administered at baseline and every year during follow-up
for 3 years. In addition, the Non-Motor Symptom Scale
(NMSS) [22], Hospital Anxiety and Depression Scale
(HADS), Questionnaire for Impulsive-Compulsive Disor-
ders in Parkinson’s Disease (QUIP) and Epworth Sleepi-
ness Scale (ESS) will be scored [23–25]. A translated
version of the structured questionnaires are provided as
Additional file 1 with this article.
Cognitive assessment
A measurement of global cognitive function will be
assessed by the Mini Mental State Examination (MMSE)
[26], Frontal Assessment Battery (FAB) [27] and Cam-
bridge Neuropsychological Automated Test Battery [28]
at baseline and after three years follow-up.
Neurological examination
Standard neurological examination will be performed in-
cluding testing of cranial nerves, motor and sensory
function, tendon reflexes and presence or absence of pri-
mary reflexes. Horizontal and vertical blood pressure
will be measured to screen for orthostatic hypotension.
In addition, the following clinimetric scales will be
assessed: Unified Parkinson’s Disease rating scale
(UPDRS) III and IV, Hoehn and Yahr disease severity
score [29] and Scale for the assessment and rating of
ataxia (SARA) [30]. The neurological examination will




All patients will have a brain MRI at first presentation
performed on 3 Tesla MRI scanner (Siemens Magnetom
Trio, Erlangen, Germany) by a standardized scanning
protocol. Conventional MRI sequences will include 3D
T1 MPrage, T2 turbo-spin echo, T2 fluid attenuated
inversed recovery (FLAIR), and proton density se-
quences. Advanced MRI sequences will include diffusion
weighted imaging (DWI) and diffusion tensor imaging
(DTI), SWI and rs-fMRI. All MRI scans will be evaluated
in a systematic fashion by two neuroradiologists blinded
for clinical symptoms and outcome. The presence of the
following abnormalities on conventional MRI sequences
will be scored using a diagnostic workstation (Agfa-
Impax version 6.5.3, Gevaert, Mortsel, Belgium): atrophy
and T2 hypo-intensity of the putamen, putaminal rim
sign, frontal lobe and parietal lobe atrophy, lateral, third
and fourth ventricle dilatation, midbrain and pontine
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Hypokinetic-rigid syndrome of
neurodegenerative origin
Disease duration < 3 years
Age > 18 years
Instable comorbidity
Incompetent patient
A medical history of brain surgery
Other neurodegenerative disorder
Diagnosis of clinically established
or probable PD
Diagnosis of probable MSA, PSP,
CBS or VP
Exclusion criteria for MRI:
Claustrophobia
Metal devices
Unable to lie still for 30 min
Pregnancy
Exclusion criteria for lumbar puncture:
Coagulation disorders
Oral anticoagulants
PD Parkinson’s disease, MSA multiple system atrophy, PSP progressive
supranuclear palsy, CBS corticobasal syndrome, VP vascular parkinsonism
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atrophy, hummingbird sign, atrophy of the cerebellum
and cerebellar vermis, atrophy of the medulla oblongata,
T2 hyper-intense signal changes of the middle cerebral
peduncle and hot cross bun sign, dilated perivascular
spaces, lacunar infarctions and white matter changes.
Advanced imaging sequences will be analyzed by dedi-
cated software packages, including ‘Functional MR Im-
aging of the Brain Software Library‘(FSL, University of
Oxford, United Kingdom) and ‘Statistical Parametric
Mapping’ (SPM, Trust Centre of Neuroimaging, London,
United Kingdom).
CSF
The following CSF variables will be analyzed according
to previously described methods [15, 31–33]: Aβ40,
Aβ42, t-tau, p-tau (phosphorylated at Thr181), α-syn,
NFL, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG),
5-hydroxyindolacetic acid (5-HIAA), homovanillic acid
(HVA), blood pigments and the total cell count. The cell
count and blood pigments will be analyzed within 2 h
after CSF collection; α-syn will be analyzed according to
previously described methods [32]; all other parameters
will be analyzed within 4 weeks after CSF collection. CSF
samples are collected in polypropylene tubes, centrifuged,
aliquoted, and stored at − 80 °C until analysis. Because the
concentrations of HVA and 5-HIAA vary in the different
fractions of CSF, we aim for separate collection of the
9th–11th ml fraction for analysis of neurotransmitter me-
tabolites, according to previously described methods [34].
Laboratory technicians blinded for clinical symptoms and
outcome will perform all CSF analyses. When patients are
taking dopaminergic medication at the time of lumbar
puncture, the results of neurotransmitter metabolites will
be excluded from the measurements.
Follow-up
During the three years after baseline examinations
patients will be followed by their own neurologist. Every
year patients are requested to complete a structured
questionnaire. After three years, all patients will be re-
examined by the study investigator (AR).
Assessment of diagnoses
Before inclusion, the referring neurologist will be asked
to establish the probable diagnosis based on routine
clinical examination. Specifically, a level of diagnostic
(un) certainty will be indicated on a scale of 0–100. After
inclusion, a movement disorder expert will also be asked
for the diagnosis and level of certainty based on the clin-
ical evaluation; a neuroradiologist makes the diagnosis
based on imaging findings and a neurochemist based on
CSF analysis.
The final clinical diagnosis will be established after
three years of follow-up in consensus by two
independent neurologists specialized in movement disor-
ders, and this will serve as the “silver standard” reference
diagnosis. This reference diagnosis will be based on the
clinical data at baseline, the disease course after 3 years
follow-up and with adherence to the following inter-
national clinical criteria: Movement Disorder Society
clinical diagnostic criteria for PD [35], Gilman criteria
for MSA [36], the movement disorder society criteria for
PSP [37], Armstrong criteria for CBS [38] and Zijlmans
criteria for vascular parkinsonism [39]. These neurolo-
gists will be blinded for the results of the ancillary inves-
tigations, except for the conventional MRI because this
is part of routine procedures in clinical practice. See Fig.
1 for a flowchart of the study design.
Outcome measures
Our primary outcome measure of interest will be the
diagnosis (e.g. PD or AP) after three years of follow-up.
The secondary outcome measure is the specific diagno-
sis (PD, MSA, PSP, etc.) after three years of follow-up.
Statistical analysis
For our first objective, the estimated initial diagnosis by
the movement disorder specialist, neuroradiologist and
neurochemist respectively will be compared to the refer-
ence diagnosis (after three years follow-up). Sensitivity,
specificity and Kappa (k) are calculated. Next, the Net
Reclassification Index (NRI) is calculated, which gives
the proportion of participants correctly (re-)classified as
having PD or AP. NRI values will be calculated for MRI
and CSF following the classification by a movement
disorder specialist [40].
For our second objective, descriptive data will be gen-
erated for all variables. Continuous variables will be pre-
sented as means ± standard deviations or medians. PD
patients will be compared with AP patients using a Stu-
dent’s t or Mann-Whitney U test, whichever appropriate.
Dichotomous variables will be compared using Chi-
square test or Fisher exact test, whichever appropri-
ate. A p-value of < 0.05 will be considered significant
(two-sided).
For each diagnostic strategy (e.g. clinical evaluation,
MRI and CSF respectively) blockwise logistic regression
with stepwise forward model selection will be used to
identify parameters with optimal diagnostic power. For
each model ROC-curves and C-statistics are calculated.
Data management and analysis will be performed
using IBM SPSS Statistics 22 (IBM Corp, Armonk, NY,
USA).
Sample size calculation
This study is exploratory in nature. We estimate that a
minimum of 30 AP and 30 PD patients will be needed
to evaluate the diagnostic value of the three diagnostic
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strategies (clinical evaluation by a movement disorder
specialist, MRI and CSF biomarkers). In our previous
cohort study of patients with parkinsonism 60% of
patients had a diagnosis of AP [34]. 30% of patients did
not complete the follow-up period of 3 years, mainly
because the participant had deceased or was too severely
affected, the majority of which was diagnosed with AP
(33 out of 46 drop-outs). Therefore, we estimate that ap-
proximately 100 participants will be needed to assess the
diagnostic accuracy of the different diagnostic tests.
Loss to follow-up
In case patients opt to withdraw from the study or are no
longer able to participate, the investigator will try to
obtain a final interview and neurological examination if
possible. When loss to follow-up is greater than 20%, ana-
lysis will be done to check for associated biased effects.
Discussion
A major unmet need in the diagnostic workup of parkin-
sonian disorders is a diagnostic tool to differentiate the
various forms of parkinsonism when the clinically based
uncertainty is high. This study is especially designed to
provide directions for the neurologist in daily practice
when the clinical picture of parkinsonism is puzzling.
Recently, we completed a similar prospective study of
156 consecutive patients with parkinsonism, but with an
initially uncertain diagnosis [34]. All patients underwent
extensive clinical testing and the following ancillary
investigations: routine brain MRI; 123I-iodobenzamide
single photon-emission computed tomography (IBZM-
SPECT); CSF analysis; and anal sphincter electromyog-
raphy (EMG).
We have shown that clinical tests such as tandem gait
analysis and the axial UPDRS sub-score had a high
predictive value to discriminate between PD and AP
[34]. NFL and tau in CSF differentiated MSA from PD
and tau and p-tau protein were elevated in CBS. None-
theless, none of the ancillary investigations, (routine
brain MRI, IBZM-SPECT, CSF analysis and anal sphinc-
ter EMG) was superior to the clinical judgment in differ-
entiating parkinsonian syndromes [34].
However, diagnostic uncertainty in this previous
cohort study was defined as being present when the
neurologist who referred the patient was uncertain about
the diagnosis (even when the patient fulfilled the prob-
able criteria for one of the parkinsonian syndromes).
Furthermore, patients from all disease stages were in-
cluded. Therefore, the proportion of patients in an early
disease stage and with an actual uncertain diagnosis was
relatively small.
For that reason, the a priori chance that ancillary
investigations would be of additional value was limited.
Moreover, no advanced MRI techniques were used.
Thus, we designed this present study to assess the diag-
nostic value of ancillary investigations in a population of
patients with parkinsonism and an unclear clinical
picture at the beginning of their disease course. We
included the judgment of a movement disorder expert in
the baseline examinations to compare its added diagnos-
tic value to the various ancillary investigations. As ancil-
lary tests, we chose brain MRI (both conventional and
advanced MRI techniques) and CSF collection because
of their potential to reveal new biomarkers for differ-
entiating PD from AP based on developments over
the past decade.
The gold standard for diagnosis of PD and the AP
remains neuropathological confirmation of the clinical
diagnosis upon post-mortem examination. However,
prior research has demonstrated that neuropathological
Fig. 1 flowchart of the study design. *A translated version of the structured questionnaires are provided as Additional file 1 with this article
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data show a high concordance between the clinical
diagnosis after three years follow-up established by a
movement disorder specialist and neuropathological
examination post-mortem [1]. Therefore, we will use the
clinical diagnosis after three years follow-up as reference
diagnosis, or ‘silver standard’, with which we compare
the results of ancillary investigations in individual
patients. In order to minimize the potential misdiagnosis
that might occur using the clinical diagnosis instead of
the neuropathological diagnosis, we require the clinical
diagnosis to be established in consensus by two neurolo-
gists highly experienced in movement disorders and
according to the international criteria.
This study will help the general neurologist select the
best available diagnostic “tool” in differentiating parkin-
sonian syndromes (e.g. clinical evaluation by a move-
ment disorder specialist, brain MRI or CSF biomarkers).
Additional file
Additional file 1: Structured questionnaire English translation. English
translation of the annual questionnaire. Description of data: English
translation of the annual questionnaire of the Parkinson’s Disease
Diagnostic Observations Study (PADDO). (PDF 758 kb)
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